Abbott Laboratories $ABT Shares Acquired by Okabena Investment Services Inc.

Key Points

• Okabena Investment Services Inc. increased its holdings in Abbott Laboratories by 990.5% in Q1, now owning 36,269 shares worth approximately $4.81 million.
• The recent quarterly dividend of $0.59 per share reflects an annualized yield of 1.8% with a payout ratio of 29.57%.
• Abbott's stock has seen a significant increase, with a quarterly revenue of $11.14 billion, up 7.4% from the previous year, and a consistent earnings per share (EPS) estimate for FY 2025 between 5.100 and 5.200.

Okabena Investment Services Inc. lifted its position in Abbott Laboratories (NYSE:ABT - Free Report) by 990.5% in the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 36,269 shares of the healthcare product maker's stock after purchasing an additional 32,943 shares during the period. Abbott Laboratories accounts for about 1.2% of Okabena Investment Services Inc.'s investment portfolio, making the stock its 18th biggest position. Okabena Investment Services Inc.'s holdings in Abbott Laboratories were worth $4,811,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the company. Cascade Investment Group Inc. boosted its holdings in shares of Abbott Laboratories by 3.6% in the first quarter. Cascade Investment Group Inc. now owns 3,464 shares of the healthcare product maker's stock valued at $460,000 after purchasing an additional 119 shares during the period. Truvestments Capital LLC lifted its holdings in Abbott Laboratories by 46.3% during the first quarter. Truvestments Capital LLC now owns 36,570 shares of the healthcare product maker's stock worth $4,851,000 after buying an additional 11,571 shares during the period. Wealth Preservation Advisors LLC purchased a new stake in Abbott Laboratories during the first quarter worth $373,000. B. Metzler seel. Sohn & Co. AG lifted its holdings in Abbott Laboratories by 87.5% during the first quarter. B. Metzler seel. Sohn & Co. AG now owns 1,715,370 shares of the healthcare product maker's stock worth $227,544,000 after buying an additional 800,735 shares during the period. Finally, Delta Investment Management LLC lifted its holdings in Abbott Laboratories by 4.8% during the first quarter. Delta Investment Management LLC now owns 6,509 shares of the healthcare product maker's stock worth $863,000 after buying an additional 298 shares during the period. Hedge funds and other institutional investors own 75.18% of the company's stock.

Abbott Laboratories Trading Down 1.2%

Shares of NYSE ABT traded down $1.53 during midday trading on Tuesday, reaching $131.13. 1,401,795 shares of the stock were exchanged, compared to its average volume of 6,721,447. The company has a 50 day simple moving average of $130.97 and a 200 day simple moving average of $131.36. The stock has a market capitalization of $228.23 billion, a P/E ratio of 16.44, a PEG ratio of 2.52 and a beta of 0.69. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT - Get Free Report) last announced its quarterly earnings results on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of $1.26. Abbott Laboratories had a net margin of 32.43% and a return on equity of 18.32%. The business had revenue of $11.14 billion during the quarter, compared to the consensus estimate of $11.01 billion. During the same quarter last year, the firm earned $1.14 EPS. The business's revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. As a group, equities analysts expect that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, August 15th. Investors of record on Tuesday, July 15th were given a $0.59 dividend. The ex-dividend date of this dividend was Tuesday, July 15th. This represents a $2.36 dividend on an annualized basis and a yield of 1.8%. Abbott Laboratories's payout ratio is 29.57%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ABT. Jefferies Financial Group raised Abbott Laboratories from a "hold" rating to a "buy" rating and upped their price target for the stock from $143.00 to $145.00 in a research report on Friday, July 18th. Wells Fargo & Company reduced their price target on Abbott Laboratories from $147.00 to $142.00 and set an "overweight" rating on the stock in a research report on Friday, July 18th. Mizuho upped their target price on Abbott Laboratories from $130.00 to $140.00 and gave the company a "neutral" rating in a research report on Wednesday, July 16th. Leerink Partners assumed coverage on Abbott Laboratories in a research report on Monday, June 16th. They set a "market perform" rating and a $143.00 price target on the stock. Finally, Morgan Stanley increased their price target on Abbott Laboratories from $127.00 to $137.00 and gave the stock an "equal weight" rating in a research report on Tuesday, July 15th. Two analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $144.47.

Insiders Place Their Bets

In other Abbott Laboratories news, CFO Philip P. Boudreau sold 5,550 shares of Abbott Laboratories stock in a transaction on Friday, August 8th. The shares were sold at an average price of $134.55, for a total value of $746,752.50. Following the transaction, the chief financial officer directly owned 51,003 shares in the company, valued at approximately $6,862,453.65. The trade was a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.46% of the stock is currently owned by company insiders.

About Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.